Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-3.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
9.9
Industry P/E
--
EV/EBITDA
-0.3
Div. Yield
0 %
Debt to Equity
0.4
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
1,800,000
CFO
$-192.01 Mln
EBITDA
$-251.78 Mln
Net Profit
$-258.63 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Organovo Holdings (ONVO)
| -64.1 | -1.5 | -55.3 | -84.1 | -59.4 | -59.4 | -46.9 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Organovo Holdings (ONVO)
| -58.3 | -21.3 | -61.2 | -70.5 | 72.9 | -62.8 | -28.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Organovo Holdings (ONVO)
|
2.0 | 3.7 | 0.1 | -12.4 | -10,272.1 | -352.5 | -- | 9.9 |
| 5.0 | 266.1 | 48.4 | -4.1 | -122.7 | -1.9 | -- | 1.2 |
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the... fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California. Read more
Company Secretary & Executive Chairman
Mr. Keith E. Murphy
Company Secretary & Executive Chairman
Mr. Keith E. Murphy
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Organovo Holdings Inc (ONVO) is $1.98 (NASDAQ) as of 23-May-2025 09:30 EDT. Organovo Holdings Inc (ONVO) has given a return of -59.42% in the last 3 years.
Since, TTM earnings of Organovo Holdings Inc (ONVO) is negative, P/E ratio is not available.
The P/B ratio of Organovo Holdings Inc (ONVO) is 9.89 times as on 23-May-2025, a 151 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Organovo Holdings Inc (ONVO) are Rs 21.96 and Rs 1.56 as of 04-Apr-2026.
Organovo Holdings Inc (ONVO) has a market capitalisation of $ 4 Mln as on 23-May-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Organovo Holdings Inc (ONVO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.